Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases, (e.g. malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should management decide to fund. But the bigger issue is how this program developed under the umbrella role Genzyme's corporate social responsibility fits into its global competitive strategy.

【書誌情報】

ページ数：23ページ

サイズ：A4

商品番号：HBSP-910407

発行日：2009/8/20

登録日：2011/2/7